Cision PR Newswire
RETA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.
News provided byLevi & Korsinsky, LLP
May 25, 2023, 9:20 PM ET
NEW YORK, May 25, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ: RETA): concerning possible violations of federal securities laws.
On May 10, 2023, Reata issued a press release announcing its financial results for the first quarter of 2023. Among other items, Reata announced its decision to discontinue studies for its kidney disease candidate bardoxolone, which the Company had previously advanced as one of its lead assets in partnership with Blackstone Life Sciences and Kyoma Kirin. On this news, Reata's stock price fell $14.99 per share or 14.23%, to close at $90.38 per share on May 10, 2023. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
View original content to download multimedia:https://www.prnewswire.com/news-releases/reta-investor-alert-levi--korsinsky-llp-notifies-investors-of-an-investigation-involving-possible-securities-fraud-violations-by-officers-of-reata-pharmaceuticals-inc-301835302.html
SOURCE Levi & Korsinsky, LLP
NOTE: This content is not written by or endorsed by "WKRN", its advertisers, or Nexstar Media Inc.